• 13 December 2018

    Rafael launches Phase III trial of pancreatic cancer drug

    Rafael Pharmaceuticals has commenced the Phase III AVENGER 500 trial to examine CPI-613 (devimistat) in combination with modified folfirinox (mFFX) as first-line therapy to treat patients with metastatic adenocarcinoma of...

Go Top